Drug Trial Radar · NCT05392114
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
154
Actual
Start
Jul 13, 2022
Primary completion
Dec 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- May 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).
Conditions
- Hereditary Angioedema
Interventions
DonidalorsenDrug
Donidalorsen will be administered by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by SeverityTime frame: Up to approximately 70 weeks, plus 104 weeks for Group 1; up to approximately 76 weeks, plus 104 weeks for Group 2
Locations
50 sites in 14 countries. Site status is shown where the registry gives one.
Ionis Investigative Site
Paradise Valley, Arizona
Ionis Investigative Site
La Jolla, California
Ionis Investigative Site
Santa Monica, California
Ionis Investigative Site
Walnut Creek, California
Ionis Investigative Site
Tampa, Florida
Ionis Investigative Site
Kansas City, Kansas
Ionis Investigative Site
Boston, Massachusetts
Ionis Investigative Site
Ann Arbor, Michigan
Ionis Investigative Site
Detroit, Michigan
Ionis Investigative Site
St Louis, Missouri
Ionis Investigative Site
Mooresville, North Carolina
Ionis Investigative Site
Cincinnati, Ohio
Ionis Investigative Site
Columbus, Ohio
Ionis Investigative Site
Hershey, Pennsylvania
Ionis Investigative Site
Dallas, Texas
Ionis Investigative Site
Murray, Utah
Ionis Investigative Site
Edegem, Belgium
Ionis Investigative Site
Sofia, Bulgaria
Ionis Investigative Site
Sofia, Bulgaria
Ionis Investigative Site
Edmonton, Canada
Ionis Investigative Site
Ottawa, Ontario, Canada
Ionis Investigative Site
La Tronche, France
Ionis Investigative Site
Marseille, France
Ionis Investigative Site
Paris, France
Ionis Investigative Site
Berlin, Germany
Ionis Investigative Site
Frankfurt, Germany
Ionis Investigative Site
München, Germany
Ionis Investigative Site
Ashkelon, Israel
Ionis Investigative Site
Haifa, Israel
Ionis Investigative Site
Tel Aviv, Israel
Ionis Investigative Site
Catania, Italy
Ionis Investigative Site
Naples, Italy
Ionis Investigative Site
Padova, Italy
Ionis Investigative Site
Palermo, Italy
Ionis Investigative Site
San Donato Milanese, Italy
Ionis Investigative Site
Amsterdam, Netherlands
Ionis Investigative Site
Groningen, Netherlands
Ionis Investigative Site
Krakow, Poland
Ionis Investigative Site
San Juan, Puerto Rico
Ionis Investigative Site
Barcelona, Spain
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.